<DOC>
	<DOCNO>NCT00063882</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray source damage tumor cell . Interstitial brachytherapy use radioactive material place directly near tumor kill tumor cell . Combining interstitial brachytherapy external-beam radiation therapy may kill tumor cell . It yet know whether interstitial brachytherapy effective without external-beam radiation therapy treat prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness interstitial brachytherapy without external-beam radiation therapy treat patient prostate cancer .</brief_summary>
	<brief_title>Interstitial Brachytherapy With Without External-Beam Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare 5-year freedom progression patient intermediate-risk prostate cancer treat interstitial brachytherapy without external beam radiotherapy ( EBRT ) . - Compare biochemical ( i.e. , prostate-specific antigen ) failure , biochemical failure Phoenix definition , disease-specific survival , local progression , distant metastasis patient treat regimen . - Compare morbidity quality life patient treat regimen . - Determine feasibility collect Medicare data large RTOG prostate cancer clinical trial cost effectiveness cost utility analysis combine treatment interstitial brachytherapy EBRT . - Prospectively collect diagnostic biopsy sample patient future biomarker analysis . OUTLINE : This randomize , multicenter study . Patients stratify accord disease stage ( T1c vs T2a T2b ) , Gleason score ( ≤ 6 vs 7 ) , prostate-specific antigen ( &lt; 10 ng/mL vs 10-20 ng/mL ) , prior neoadjuvant hormonal therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo external beam radiotherapy 5 day week 5 week . Within 2-4 week radiotherapy , patient undergo interstitial brachytherapy iodine I 125 palladium Pd 103 seed . - Arm II : Patients undergo interstitial brachytherapy , arm I . Quality life assess baseline , 4 , 12 , 24 month , annually 3 year . After completion study treatment , patient follow 3-5 week , 4 , 6 , 9 , 12 month , every 6 month 4 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate T1cT2b , N0 , M0 Intermediaterisk disease , define 1 following : Gleason score &lt; 7 AND prostatespecific antigen ( PSA ) 1020 ng/mL Gleason score 7 AND PSA &lt; 10 ng/mL No evidence distant metastasis Prostate volume ≤ 60 cc transrectal ultrasonography American Urological Association void symptom score great 15 ( alpha blocker allow ) PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Patients must use effective contraception No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ site No major medical psychiatric illness would preclude study therapy No hip prosthesis PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Prior neoadjuvant hormonal therapy allow provide follow true : Therapy initiate within 26 month study enrollment Therapy 6 month duration Use 5alpha reductase inhibitor ( e.g. , finasteride ) discontinue registration No concurrent hormonal therapy Radiotherapy No prior pelvic radiotherapy Surgery No prior radical surgery prostate cancer No prior transurethral resection prostate No prior cryosurgery Other No prior transurethral needle ablation prostate No prior transurethral microwave thermotherapy prostate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>